Başer, Onur
Loading...
Profile URL
Name Variants
Job Title
Email Address
basero@mef.edu.tr
Main Affiliation
04. Faculty of Economics, Administrative and Social Sciences
Status
Former Staff
Website
ORCID ID
Scopus Author ID
Turkish CoHE Profile ID
Google Scholar ID
WoS Researcher ID
No research topics data found.
Sustainable Development Goals
1NO POVERTY
0
Research Products
2ZERO HUNGER
0
Research Products
3GOOD HEALTH AND WELL-BEING
44
Research Products
4QUALITY EDUCATION
0
Research Products
5GENDER EQUALITY
0
Research Products
6CLEAN WATER AND SANITATION
0
Research Products
7AFFORDABLE AND CLEAN ENERGY
0
Research Products
8DECENT WORK AND ECONOMIC GROWTH
0
Research Products
9INDUSTRY, INNOVATION AND INFRASTRUCTURE
0
Research Products
10REDUCED INEQUALITIES
10
Research Products
11SUSTAINABLE CITIES AND COMMUNITIES
0
Research Products
12RESPONSIBLE CONSUMPTION AND PRODUCTION
0
Research Products
13CLIMATE ACTION
0
Research Products
14LIFE BELOW WATER
0
Research Products
15LIFE ON LAND
0
Research Products
16PEACE, JUSTICE AND STRONG INSTITUTIONS
1
Research Products
17PARTNERSHIPS FOR THE GOALS
2
Research Products
This researcher does not have a Scopus ID.
Documents
0
Citations
0
No records found in other affiliations.
Scholarly Output
96
Articles
27
Views / Downloads
17858/94440
Supervised MSc Theses
0
Supervised PhD Theses
0
WoS Citation Count
399
Scopus Citation Count
440
Patents
0
Projects
0
WoS Citations per Publication
4.16
Scopus Citations per Publication
4.58
Open Access Source
22
Supervised Theses
0
| Journal | Count |
|---|---|
| Value in Health | 31 |
| International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting. | 18 |
| International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual European Congress | 5 |
| International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting | 4 |
| American Heart Association (AHA) Scientific Sessions 2015 | 2 |
Current Page: 1 / 8
Scopus Quartile Distribution
Competency Cloud
96 results
Scholarly Output Search Results
Now showing 1 - 10 of 96
Conference Object Evaluating the Economic Burden and Health Care Utilization of Coronary Artery Disease in the Us Medi-Cal Population(2016) Zhang, Q; Zhao, Y; Keshishian, A; Xie, L; Yuce, H; Başer, Onur...Conference Object A Comparative Analysis of the Health Care Utilization and Costs of Patients Diagnosed With and Without Liver Cancer in the Us Medicare Population(2017) Ogbomo, A.; Lin, Y.; Keshishian, A; Xie, L; Yuce, H; Başer, Onur...Conference Object Spatial Distribution of the Total Number of Medical Devices in Turkey: a Classification Analysis(Elsevier Science Inc, 2016) Cinaroğlu, S.; Başer, OnurObjectives: The unbalanced distribution of medical technologies and devices between rural and urban areas is a major problem for developing countries including Turkey. After the establishment of Public Hospital Unions (PHUs) in Turkey, legislative changes were made to improve the autonomy of public hospitals. This study utilizes spatial analysis to assess the distribution of medical device use in Turkey using PHUs as a decision making unit. Methods: Data from the PHUs’ statistics year book for the year 2014 was assessed. The total number of PHUs is 89. A Hierarchical cluster analysis was performed to classify PHUs according to the total number of medical devices. The Euclidean distance measure and Wards methods were used in the analysis for classification. Results: Study results show that, in Turkey, PHUs were categorized into two clusters based on the total number of medical devices available. Regarding the spatial distribution of the clusters, the first cluster represents PHUs in rural areas, and the second represents PHUs located in urban areas of Turkey. PHUs representing large cities with high population density were included in one cluster, and all other PHUs were included in the second. Statistical test results indicated that the two clusters differ according to the total number of magnetic resonance imaging (MRI: t= -14.10, p< 0.01), computed tomography (CT) scan (t= -15.75, p< 0.01), mammography (t= -11.40, p< 0.01), ultrasonography (t= -14.62, p< 0.01), and electrocardiography (EKG; t= -12.29, p< 0.01) equipment available. Conclusions: It is advisable for health policy makers and health technology assessment authorities in Turkey to focus on the differences between rural and urban areas of the country when determining the need for medical devices.Conference Object Trends in Prevalence and Incidence Rates of Type 2 Diabetes Mellitus in the Medicare Population(2015) Xie, L; Wang, Y; Tan, H; Ogbomo, A; Başer, Onur; Yuce H....Conference Object Mortality and Rehospitalization Rates Among Hospitalized Congestive Heart Failure Patients in the Us Medicare Population(2016) Pandya S; Du, H; Wang, L; Yuce, H; Başer, Onur...Conference Object Demographic and Clinical Characteristics of Patients With Polycythemia Vera (pv) in the Us Veterans Population(2016) Parasuraman S; Yu J; Paranagama D; Shrestha S; Wang L,; Başer, Onur...Article Citation - WoS: 15Citation - Scopus: 15Economic Outcomes in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide or Abiraterone Acetate Plus Prednisone(Springer, 2020) Lechpammer, Stanislav; Ramaswamy, Krishnan; Wang, Li; Mardekian, Jack; George, Daniel J.; Sandin, Rickard; Schultz, Neil M.; Başer, Onur; Huang, AhongIntroduction: Prostate cancer (PC) is the second leading cause of cancer death among US men and accounts for considerable healthcare expenditures. We evaluated economic outcomes in men with chemotherapy-naı¨ve metastatic castration-resistant PC (mCRPC) treated with enzalutamide or abiraterone acetate plus prednisone (abiraterone). Methods: We performed a retrospective analysis on 3174 men (18 years or older) utilizing the Veterans Health Administration (VHA) database from 1 April 2014 to 31 March 2018. Men with mCRPC were included if they had at least one pharmacy claim for enzalutamide or abiraterone (first claim date = index date) following surgical or medical castration, had no chemotherapy treatment within 12 months prior to the index date, and had continuous VHA enrollment for at least 12 months pre- and post-index date. Men were followed until death, disenrollment, or end of study and were 1:1 propensity score matched (PSM). All-cause and PC-related resource use and costs per patient per month (PPPM) in the 12 months post index were compared between matched cohorts. Results: We identified 1229 men with mCRPC prescribed enzalutamide and 1945 prescribed abiraterone with mean ages of 74 and 73 years, respectively. After PSM, each cohort had 1160 patients. The enzalutamide cohort had fewer all-cause (2.51 vs 2.86; p\0.0001) and PC-related outpatient visits (0.86 vs 1.03; p\0.0001), with corresponding lower all-cause ($2588 vs $3115; p\0.0001) and PC-related ($1356 vs $1775; p\0.0001) PPPM outpatient costs compared with the abiraterone cohort. Allcause total costs (medical and pharmacy) PPPM ($8085 vs $9092; p = 0.0002) and PC-related total costs PPPM ($6321 vs $7280; p\0.0001) were significantly lower in the enzalutamide cohort compared with the abiraterone cohort. Conclusions: Enzalutamide-treated men with chemotherapy-naı ¨ve mCRPC had significantly lower resource utilization and healthcare costs compared with abiraterone-treated men. Plain Language Summary: Plain language summary available for this article.Conference Object Examining the Incidence and Prevalence of Bipolar Disorder Among U.s. Veteran Patients From 2011 To 2015(2016) Bashyal, R; Du, H; Wang, L; Başer, Onur...Conference Object Examining the Incidence and Prevalence of Alcohol Dependence Among Us Veteran Patients(2016) Bashyal, R; Du, H; Wang, L; Başer, Onur...Article Creating National Weights for a Patient-Level Longitudinal Database(2016) Başer, Onur; Li Wang; Maguire J.To create a nationally-representative estimate from longitudinal data by controlling for sociodemographic factors and health status. The Agency for Healthcare Research and Quality’s (AHRQ) Medicare Expenditures Panel Survey (MEPS) was used as the basis for adjustment methodology. MEPS is a data source representing health insurance coverage cost and utilization, and comprises several large-scale surveys of families, individuals, employers, and health care providers. Using these data, we created subset populations. We then used multivariate logistic regression to construct demographics and case-mix-based weights, which were applied to create a population sample that is similar to the national population. The weight was derived using the inverse probability of the weighting approach, as well as a raking mechanism. We compared the results with the projected number of persons in the US population in the same categories to examine the validity of the weights. The following variables were used in the logistic regression: Age group, gender, race, location, income level and health status (Charlson Comorbidity Index scores and chronic condition diagnosis). Relative to MEPS data, patients included in the private insurance data were more likely to be male, older, to have a chronic condition, and to be white (p=0.0000). Adjusted weighted values for patients in the commercial group ranged from 15.47 to 36.36 (median: 16.91). Commercial insurance and MEPS data populations were similar in terms of their socioeconomic and clinical categories. As an outcomes measure, the predicted annual number of patients with prescription claims from private insurance data was 6 963 034. The annual number of statin users were predicted as 6 709 438 using weighted MEPS data. National projections of large-scale patient longitudinal databases require adjustment utilizing demographic factors and case-mix differences related to health status.